Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164481024> ?p ?o ?g. }
- W2164481024 endingPage "1760" @default.
- W2164481024 startingPage "1754" @default.
- W2164481024 abstract "Background This Phase 2 study tested the tolerability and efficacy of bortezomib combined with reinduction chemotherapy for pediatric patients with relapsed, refractory or secondary acute myeloid leukemia (AML). Correlative studies measured putative AML leukemia initiating cells (AML-LIC) before and after treatment. Procedure Patients with <400 mg/m2 prior anthracycline received bortezomib combined with idarubicin (12 mg/m2 days 1–3) and low-dose cytarabine (100 mg/m2 days 1–7) (Arm A). Patients with ≥400 mg/m2 prior anthracycline received bortezomib with etoposide (100 mg/m2 on days 1–5) and high-dose cytarabine (1 g/m2 every 12 hours for 10 doses) (Arm B). Results Forty-six patients were treated with 58 bortezomib-containing cycles. The dose finding phase of Arm B established the recommended Phase 2 dose of bortezomib at 1.3 mg/m2 on days 1, 4, and 8 with Arm B chemotherapy. Both arms were closed after failure to meet predetermined efficacy thresholds during the first stage of the two-stage design. The complete response (CR + CRp) rates were 29% for Arm A and 43% for Arm B. Counting additional CRi responses (CR with incomplete neutrophil recovery), the overall CR rates were 57% for Arm A and 48% for Arm B. The 2-year overall survival (OS) was 39 ± 15%. Correlative studies showed that LIC depletion after the first cycle was associated with clinical response. Conclusion Bortezomib is tolerable when added to chemotherapy regimens for relapsed pediatric AML, but the regimens did not exceed preset minimum response criteria to allow continued accrual. This study also suggests that AML-LIC depletion has prognostic value. Pediatr Blood Cancer 2014; 61:1754–1760. © 2014 Wiley Periodicals, Inc." @default.
- W2164481024 created "2016-06-24" @default.
- W2164481024 creator A5004059613 @default.
- W2164481024 creator A5008703987 @default.
- W2164481024 creator A5021003209 @default.
- W2164481024 creator A5052343172 @default.
- W2164481024 creator A5058663906 @default.
- W2164481024 creator A5066861312 @default.
- W2164481024 creator A5067486820 @default.
- W2164481024 creator A5073322914 @default.
- W2164481024 creator A5076408794 @default.
- W2164481024 creator A5079657944 @default.
- W2164481024 creator A5080912335 @default.
- W2164481024 creator A5084489076 @default.
- W2164481024 creator A5088620010 @default.
- W2164481024 date "2014-06-29" @default.
- W2164481024 modified "2023-09-29" @default.
- W2164481024 title "A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group" @default.
- W2164481024 cites W1967358345 @default.
- W2164481024 cites W1972995249 @default.
- W2164481024 cites W1976582166 @default.
- W2164481024 cites W1980032822 @default.
- W2164481024 cites W1980521997 @default.
- W2164481024 cites W1988356885 @default.
- W2164481024 cites W1999042605 @default.
- W2164481024 cites W2002213310 @default.
- W2164481024 cites W2018591383 @default.
- W2164481024 cites W2021663709 @default.
- W2164481024 cites W2024763401 @default.
- W2164481024 cites W2026042590 @default.
- W2164481024 cites W2027364921 @default.
- W2164481024 cites W2037825770 @default.
- W2164481024 cites W2043722634 @default.
- W2164481024 cites W2046398696 @default.
- W2164481024 cites W2048385227 @default.
- W2164481024 cites W2051121908 @default.
- W2164481024 cites W2053728180 @default.
- W2164481024 cites W2066064966 @default.
- W2164481024 cites W2074725580 @default.
- W2164481024 cites W2078785519 @default.
- W2164481024 cites W2079935562 @default.
- W2164481024 cites W2084958083 @default.
- W2164481024 cites W2090757708 @default.
- W2164481024 cites W2093353574 @default.
- W2164481024 cites W2100608938 @default.
- W2164481024 cites W2107154392 @default.
- W2164481024 cites W2108235071 @default.
- W2164481024 cites W2108522140 @default.
- W2164481024 cites W2110496778 @default.
- W2164481024 cites W2119536608 @default.
- W2164481024 cites W2121565126 @default.
- W2164481024 cites W2124631783 @default.
- W2164481024 cites W2130025456 @default.
- W2164481024 cites W2135140338 @default.
- W2164481024 cites W2135478624 @default.
- W2164481024 cites W2143995836 @default.
- W2164481024 cites W2144466728 @default.
- W2164481024 cites W2149430154 @default.
- W2164481024 cites W2150003781 @default.
- W2164481024 cites W2151224270 @default.
- W2164481024 cites W2154131842 @default.
- W2164481024 cites W2159507916 @default.
- W2164481024 cites W2161418339 @default.
- W2164481024 cites W2170220752 @default.
- W2164481024 cites W2409723816 @default.
- W2164481024 cites W4376595466 @default.
- W2164481024 doi "https://doi.org/10.1002/pbc.25117" @default.
- W2164481024 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4247259" @default.
- W2164481024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24976003" @default.
- W2164481024 hasPublicationYear "2014" @default.
- W2164481024 type Work @default.
- W2164481024 sameAs 2164481024 @default.
- W2164481024 citedByCount "44" @default.
- W2164481024 countsByYear W21644810242014 @default.
- W2164481024 countsByYear W21644810242015 @default.
- W2164481024 countsByYear W21644810242016 @default.
- W2164481024 countsByYear W21644810242017 @default.
- W2164481024 countsByYear W21644810242018 @default.
- W2164481024 countsByYear W21644810242019 @default.
- W2164481024 countsByYear W21644810242020 @default.
- W2164481024 countsByYear W21644810242021 @default.
- W2164481024 countsByYear W21644810242022 @default.
- W2164481024 countsByYear W21644810242023 @default.
- W2164481024 crossrefType "journal-article" @default.
- W2164481024 hasAuthorship W2164481024A5004059613 @default.
- W2164481024 hasAuthorship W2164481024A5008703987 @default.
- W2164481024 hasAuthorship W2164481024A5021003209 @default.
- W2164481024 hasAuthorship W2164481024A5052343172 @default.
- W2164481024 hasAuthorship W2164481024A5058663906 @default.
- W2164481024 hasAuthorship W2164481024A5066861312 @default.
- W2164481024 hasAuthorship W2164481024A5067486820 @default.
- W2164481024 hasAuthorship W2164481024A5073322914 @default.
- W2164481024 hasAuthorship W2164481024A5076408794 @default.
- W2164481024 hasAuthorship W2164481024A5079657944 @default.
- W2164481024 hasAuthorship W2164481024A5080912335 @default.
- W2164481024 hasAuthorship W2164481024A5084489076 @default.
- W2164481024 hasAuthorship W2164481024A5088620010 @default.
- W2164481024 hasBestOaLocation W21644810242 @default.